Exhale Therapeutics

Exhale Therapeutics is a biotechnology company specializing in the development of inhaled biotherapeutics for respiratory and rare diseases. The company's core technology focuses on the pulmonary delivery of large molecules, such as proteins, to treat conditions like Alpha-1 Antitrypsin Deficiency (AATD). By delivering treatments directly to the lungs, Exhale aims to improve therapeutic efficacy and patient convenience compared to standard intravenous therapies. The company was founded by renowned scientists David Edwards and Robert Langer, leveraging advanced aerosol science. In January 2021, Exhale Therapeutics was acquired by Takeda Pharmaceutical Company to bolster its rare genetics and hematology pipeline.